Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study
Journal of Thrombosis and Thrombolysis · 2025
DOI: 10.1007/s11239-025-03086-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Thrombolysis, 2025. Verfasst von Junmin Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Venous Thromboembolism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Lung cancer patients are at increased risk of venous thromboembolism (VTE) and arterial thrombosis, particularly when treated with immune checkpoint inhibitors (ICIs). The Khorana Risk Score (KRS), an effective tool for predicting VTE risk in chemotherapy recipients, needs further validation in lung cancer patients treated with ICIs. METHODS: We utilized a global database and conducted a retrospective cohort study. Lung cancer patients receiving ICIs were classified into intermediate (KRS 1-2) and high-risk (KRS ≥ 3) groups. The primary outcome was VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE); secondary outcomes included arterial thrombosis and all-cause mortality. Risk comparisons were performed using Cox proportional hazards analysis. RESULTS: Among 5,378 patients, those with a high KRS had a greater risk of VTE (HR: 1.38, 95% CI: 1.15-1.65), including DVT (HR: 1.43, 95% CI: 1.12-1.82) and PE (HR: 1.32, 95% CI: 1.05-1.67). High KRS was also associated with increased arterial thrombosis (HR: 1.60, 95% CI: 1.29-1.96), ischemic stroke (HR: 1.73, 95% CI: 1.32-2.25), and elevated mortality (HR: 1.66, 95% CI: 1.48-1.87). CONCLUSION: A high KRS (≥ 3) is associated with a higher risk of thrombotic events and mortality in lung cancer patients treated with ICIs. These findings suggest that KRS may aid risk stratification in this population, warranting further prospective research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
- Department of Integrated Biology and Physiology, University of California (UCLA), Los Angeles, CA, USA.
- Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea.
- Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA.
- Section of Neurosurgery, Department of Surgery, College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan.
- Department of Medicine, Mount Auburn Hospital, Harvard Medical School, 330 Mt Auburn St, Cambridge, MA, 02138, USA. chohan.chiang@mah.harvard.edu.
Zitieren
APA
Song, J., Morgan, A. A., Abram, A. M. D., Hong, D., Kim, G., Li, W. F., Ahn, J., Chang, Y., Chi, K. Y., & Chiang, C. H. (2025). Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study. Journal of Thrombosis and Thrombolysis. https://doi.org/10.1007/s11239-025-03086-2
Vancouver
Song J, Morgan AA, Abram AMD, Hong D, Kim G, Li WF, et al. Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study. Journal of Thrombosis and Thrombolysis. 2025. doi:10.1007/s11239-025-03086-2
BibTeX
@article{Song2025,
author = {Song, Junmin and Morgan, Ahmed Ashraf and Abram, Ana Maria Diaz and Hong, Daniel and Kim, Gagi and Li, Wing Fai and Ahn, Jaeun and Chang, Yu and Chi, Kuan-Yu and Chiang, Cho-Han},
title = {Khorana risk score in lung cancer patients treated with immune checkpoint inhibitors: a real-world study},
journal = {Journal of Thrombosis and Thrombolysis},
year = {2025},
doi = {10.1007/s11239-025-03086-2}
}
EUVIMED